Browsing ICR Divisions by author "Jones, Robin"
Now showing items 1-20 of 54
-
Acral myxoinflammatory fibroblastic sarcoma with hybrid features of hemosiderotic fibrolipomatous tumor occurring 10 years after renal transplantation.
Hallin, M; Miki, Y; Hayes, AJ; Jones, RL; Fisher, C; et al. (2018-01)Myxoinflammatory fibroblastic sarcoma is a rare malignant soft tissue neoplasm that typically arises on the distal extremities of adults. It usually behaves in a low-grade manner and its characteristic histology is of a ... -
Adjuvant Imatinib in Patients with GIST Harboring Exon 9 KIT Mutations: Results from a Multi-institutional European Retrospective Study.
Vincenzi, B; Napolitano, A; Fiocco, M; Mir, O; Rutkowski, P; et al. (2021-10-06)<h4>Purpose</h4>The effect of high-dose imatinib (800 mg/day) on survival in the adjuvant treatment of patients with resected KIT exon 9-mutated gastrointestinal stromal tumors (GIST) is not established. Here, the association ... -
Aggressive fibromatosis response to tamoxifen: lack of correlation between MRI and symptomatic response.
Libertini, M; Mitra, I; van der Graaf, WTA; Miah, AB; Judson, I; et al. (2018-01)Background One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, ... -
Anthracycline, Gemcitabine, and Pazopanib in Epithelioid Sarcoma: A Multi-institutional Case Series.
Frezza, AM; Jones, RL; Lo Vullo, S; Asano, N; Lucibello, F; et al. (2018-09-13)Importance:Epithelioid sarcoma (ES) is an exceedingly rare malignant neoplasm with distinctive pathologic, molecular, and clinical features as well as the potential to respond to new targeted drugs. Little is known on the ... -
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.
Pollack, SM; Redman, MW; Baker, KK; Wagner, MJ; Schroeder, BA; et al. (AMER MEDICAL ASSOC, 2020-11-01)IMPORTANCE: Anthracycline-based therapy is standard first-line treatment for most patients with advanced and metastatic sarcomas. Although multiple trials have attempted to show improved outcomes in patients with soft-tissue ... -
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial (vol 21, pg 935, 2020)
Heinrich, MC; Jones, RL; von Mehren, M; Schoffski, P; Serrano, C; et al. (ELSEVIER SCIENCE INC, 2020-09-01) -
Avapritinib in Patients With Advanced Gastrointestinal Stromal Tumors Following at Least Three Prior Lines of Therapy.
George, S; Jones, RL; Bauer, S; Kang, Y-K; Schöffski, P; et al. (WILEY, 2021-02-01)BACKGROUND: Most gastrointestinal stromal tumors (GIST) driven by KIT or platelet-derived growth factor receptor A (PDGFRA) mutations develop resistance to available tyrosine kinase inhibitor (TKI) treatments. NAVIGATOR ... -
Avapritinib in unresectable or metastatic PDGFRA D842V-mutant gastrointestinal stromal tumours: Long-term efficacy and safety data from the NAVIGATOR phase I trial.
Jones, RL; Serrano, C; von Mehren, M; George, S; Heinrich, MC; et al.Background PDGFRA D842V mutations occur in 5-10% of gastrointestinal stromal tumours (GISTs), and previously approved tyrosine kinase inhibitors (TKIs) are inactive against this mutation. Consequently, patients have a poor ... -
Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study.
Kang, Y-K; George, S; Jones, RL; Rutkowski, P; Shen, L; et al. (LIPPINCOTT WILLIAMS & WILKINS, 2021-10-01)PURPOSE: Primary or secondary mutations in KIT or platelet-derived growth factor receptor alpha (PDGFRA) underlie tyrosine kinase inhibitor resistance in most GI stromal tumors (GISTs). Avapritinib selectively and potently ... -
Beyond the Driver Mutation: Immunotherapies in Gastrointestinal Stromal Tumors.
Roulleaux Dugage, M; Jones, RL; Trent, J; Champiat, S; Dumont, S (FRONTIERS MEDIA SA, 2021-08-20)Gastrointestinal stromal tumors (GISTs) are a subtype of soft tissue sarcoma (STS), and have become a concept of oncogenic addiction and targeted therapies.The large majority of these tumors develop after a mutation in KIT ... -
Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
Jones, RL; Herzog, TJ; Patel, SR; von Mehren, M; Schuetze, SM; et al. (2021-05-07)Background As with other alkylating agents, cardiac dysfunction can occur with trabectedin therapy for advanced soft tissue sarcomas (STS) or recurrent ovarian cancer (ROC) where treatment options for advanced disease are ... -
CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.
Schroeder, BA; LaFranzo, NA; LaFleur, BJ; Gittelman, RM; Vignali, M; et al. (BMJ PUBLISHING GROUP, 2021-08-01)BACKGROUND: Dedifferentiated liposarcoma (DDLPS) is one of the most common soft tissue sarcoma subtypes and is devastating in the advanced/metastatic stage. Despite the observation of clinical responses to PD-1 inhibitors, ... -
Clinical activity of ripretinib in patients with advanced gastrointestinal stromal tumor harboring heterogenous KIT/PDGFRA mutations in the phase 3 INVICTUS study.
Bauer, S; Heinrich, MC; George, S; Zalcberg, JR; Serrano, C; et al. (2021-09-09)Purpose Most patients with gastrointestinal stromal tumor (GIST) have activating mutations in KIT/PDGFRA and are initially responsive to tyrosine kinase inhibitors (TKIs). The acquisition of secondary mutations leads to ... -
Clinical Benefit of Ripretinib Dose Escalation After Disease Progression in Advanced Gastrointestinal Stromal Tumor: An Analysis of the INVICTUS Study.
Zalcberg, JR; Heinrich, MC; George, S; Bauer, S; Schöffski, P; et al. (WILEY, 2021-08-16)BACKGROUND: Ripretinib 150 mg once daily (QD) is indicated for advanced gastrointestinal stromal tumors (GISTs) as at least fourth-line therapy. In INVICTUS, ripretinib intrapatient dose escalation (IPDE) to 150 mg b.i.d. ... -
Clinical Characteristics and efficacy of chemotherapy in sclerosing epithelioid fibrosarcoma.
Chew, W; Benson, C; Thway, K; Hayes, A; Miah, A; et al. (2018-09-05)<h4>Background</h4>Sclerosing epithelioid fibrosarcoma (SEF) is a very rare soft tissue sarcoma subtype. Clinically it is an aggressive tumour; however, to our knowledge there are no published reports regarding the efficacy ... -
Clinicopathological features and treatment outcome of oesophageal gastrointestinal stromal tumour (GIST): A large, retrospective multicenter European study.
Mohammadi, M; IJzerman, NS; Hohenberger, P; Rutkowski, P; Jones, RL; et al. (2021-03-31)Background Oesophageal gastrointestinal stromal tumours (GISTs) account for ≤1% of all GISTs. Consequently, evidence to guide clinical decision-making is limited.Methods Clinicopathological features and outcomes in patients ... -
Controversies in the management of patients with soft tissue sarcoma: Recommendations of the Conference on State of Science in Sarcoma 2022.
Rothermundt, C; Andreou, D; Blay, J-Y; Brodowicz, T; Desar, IME; et al. (ELSEVIER SCI LTD, 2022-11-16)BACKGROUND: Owing to the rarity and heterogeneity in biology and presentation, there are multiple areas in the diagnosis, treatment and follow-up of soft tissue sarcoma (STS), with no, low-level or conflicting evidence. ... -
Durable tumor regression in highly refractory metastatic KIT/PDGFRA wild-type GIST following treatment with nivolumab.
Schroeder, BA; Kohli, K; O'Malley, RB; Kim, TS; Jones, RL; et al. (TAYLOR & FRANCIS INC, 2020-01-01)Gastrointestinal stromal tumor (GIST) is a devastating disease, especially in the setting of metastasis. The natural progression of GIST has been significantly altered by the development of small molecule tyrosine kinase ... -
Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma.
Janku, F; Bauer, S; Shoumariyeh, K; Jones, RL; Spreafico, A; et al. (ELSEVIER, 2022-08-01)BACKGROUND: Ripretinib, a broad-spectrum KIT and platelet-derived growth factor receptor A switch-control tyrosine kinase inhibitor, is approved for the treatment of adult patients with advanced gastrointestinal stromal ... -
Ending 40 years of silence: Rationale for a new staging system for soft tissue sarcoma of the head and neck.
Hahn, E; Huang, SH; Hosni, A; Razak, AA; Jones, RL; et al. (ELSEVIER IRELAND LTD, 2019-02-01)The tumor, node, metastases (TNM) anatomic staging system plays a pivotal role in cancer care, research, and cancer control activities. Since the first edition of the American Joint Committee on Cancer TNM staging ...